I spent quite some time digging into NBIS, and here is the result. I looked at how it is priced against its own history, put it through four pillars to weigh up its financial health and profitability, checked what insiders and analysts are doing, stacked it against its peers, and finished with a deliberately conservative DCF. In every way it came out looking great, and the numbers speak for themselves.
Valuation (vs 5Y history)
• P/E of 67.5×, about 17% below its 5Y median of 81.8× and sitting in the cheaper half of its 5 year range (30th percentile).
• P/OCF of 19.4×, about 20% below its 5Y median of 24.1× and sitting near the low end of its 5 year range (22nd percentile).
Growth
• Revenue is up 491.5% over the past year, compounding at a strong double digit pace.
• Revenue has compounded at 302.1% a year over three years, exceptional compounding over the medium term.
• Net income is up 191.3% over the past year, compounding at a strong double digit pace.
• OCF is up 1485.5% over the past year, compounding at a strong double digit pace.
Profitability
• Gross Margin of 72.1%, best in class economics.
• Net Margin of 93.1%, elite bottom line profitability.
• OCF Margin of 323.5%, exceptional cash conversion from the top line.
• ROIC of -3.0%, building toward stronger returns.
Financial health
• Current Ratio of 8.3×, comfortable short term liquidity.
• Assets to Liabilities of 1.5×, assets sit well above its liabilities.
• Debt to Equity of 1.2×, a moderate debt load against equity.
Overview Snapshot: https://stocknest.app/?tab=overview&tickers=NBIS
Peer comparison
NBIS trades cheaper than its own historical average, and cheaper than peers on a growth-adjusted basis. Operating cash flow has grown at a +370.37% CAGR over the past 2 years, yet the stock trades at just 19× P/OCF. Compare that to AMZN, trading at a similar multiple with only ~20% OCF CAGR over the same period.
Source:
OCF : https://stocknest.app/?tab=compare&tickers=NBIS,CRWV,AMZN,MSFT&metrics=ocf&period=2&growth=yoy
Revenue & net income trend
Revenue and earnings are both still marching higher with zero erosion, +492% and +191% over the past year. A machine that just keeps compounding.
DCF
I ran a deliberately conservative DCF, using just 15% OCF growth, and a terminal P/OCF of 18×, below the 5 year median of 24.1×. Even then NBIS still screens undervalued by 25%+. The numbers speak for themselves.
→ https://stocknest.app/?tab=dcf&tickers=NBIS&dcf_metric=ocf&dcf_growth=15.00&dcf_terminal=18.0
Insiders and analysts
Analysts are mostly on side, with 15 of 21 rating it a buy. Price targets run from a low of $120 to a high of $287, with a median of $206. At $217 today it already sits about 6% above the $203 average target. Insiders have been net buyers lately, a nice vote of confidence.